Abstract
Background: Approximately 10–15% of patients on DOACs have to interrupt their anticoagulant before an invasive procedure every year. The perioperative management and monitoring of DOACs have proved to be challenging, as differences in patients’ status and in the invasiveness of each procedure develop different situations that need a tailored therapeutic approach to each patient’s needs.
Methods: This review aims to summarize current evidence on the perioperative management of DOACs in patients undergoing a vascular surgical procedure focusing with a practical approach on three key clinical questions: (i) can we stop DOAC therapy before the vascular procedure? (ii) is bridging therapy necessary? and (iii) which is the best perioperative strategy for interruption and resumption of the anticoagulant therapy?
Results: No specific data exist for the perioperative management of vascular surgery patients on DOACs, as most studies include low number of such patients. Therapeutic strategy on how to handle DOACs perioperatively must be based on their half-life, the bleeding risk of the invasive procedures, and on the thromboembolic risk of the patient. Renal function plays a crucial role in such situations, increasing thromboembolic and bleeding risk. In general, DOACs should be stopped 2 days for high bleed risk, 1 day for low risk and should be resumed 48-72 hrs after high risk, 24 hrs after low-risk procedure. Bridging is almost never needed.
Conclusion: Further perioperative research studies on patients undergoing vascular surgery are needed to confirm whether currently accepted therapeutic perioperative strategy is appropriate for these patients.
Keywords: Vascular surgery, anticoagulants, perioperative period, invasive procedures, DOAC, bridging therapy.
Current Pharmaceutical Design
Title:Perioperative Management of DOACs in Vascular Surgery: A Practical Approach
Volume: 24 Issue: 38
Author(s): George Kouvelos*, Miltiadis Matsagkas, Nikolaos Rousas, Petroula Nana, Konstantinos Mpatzalexis, Konstantinos Stamoulis, Athanasios Giannoukas and Eleni Arnaoutoglou
Affiliation:
- Department of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa,Greece
Keywords: Vascular surgery, anticoagulants, perioperative period, invasive procedures, DOAC, bridging therapy.
Abstract: Background: Approximately 10–15% of patients on DOACs have to interrupt their anticoagulant before an invasive procedure every year. The perioperative management and monitoring of DOACs have proved to be challenging, as differences in patients’ status and in the invasiveness of each procedure develop different situations that need a tailored therapeutic approach to each patient’s needs.
Methods: This review aims to summarize current evidence on the perioperative management of DOACs in patients undergoing a vascular surgical procedure focusing with a practical approach on three key clinical questions: (i) can we stop DOAC therapy before the vascular procedure? (ii) is bridging therapy necessary? and (iii) which is the best perioperative strategy for interruption and resumption of the anticoagulant therapy?
Results: No specific data exist for the perioperative management of vascular surgery patients on DOACs, as most studies include low number of such patients. Therapeutic strategy on how to handle DOACs perioperatively must be based on their half-life, the bleeding risk of the invasive procedures, and on the thromboembolic risk of the patient. Renal function plays a crucial role in such situations, increasing thromboembolic and bleeding risk. In general, DOACs should be stopped 2 days for high bleed risk, 1 day for low risk and should be resumed 48-72 hrs after high risk, 24 hrs after low-risk procedure. Bridging is almost never needed.
Conclusion: Further perioperative research studies on patients undergoing vascular surgery are needed to confirm whether currently accepted therapeutic perioperative strategy is appropriate for these patients.
Export Options
About this article
Cite this article as:
Kouvelos George*, Matsagkas Miltiadis , Rousas Nikolaos, Nana Petroula , Mpatzalexis Konstantinos , Stamoulis Konstantinos , Giannoukas Athanasios and Arnaoutoglou Eleni , Perioperative Management of DOACs in Vascular Surgery: A Practical Approach, Current Pharmaceutical Design 2018; 24 (38) . https://dx.doi.org/10.2174/1381612825666181226154746
DOI https://dx.doi.org/10.2174/1381612825666181226154746 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review
Current Cardiology Reviews Regulatory Role of Brg1 and Brm in the Vasculature: From Organogenesis to Stress-Induced Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews Potential Usefulness of Clopidogrel Pharmacogenetics in Ce rebral Endovascular Procedures and Carotid Artery Stenting
Current Clinical Pharmacology Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Current Cancer Drug Targets Antiplatelet Therapy in Patients with Diabetes Mellitus
Current Vascular Pharmacology Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety The Relationship Between Hypertensive Retinopathy and Angiotensin Converting Enzyme Gene Polymorphism
Cardiovascular & Hematological Disorders-Drug Targets The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review
Current Stem Cell Research & Therapy Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design An Overview of the Latest Applications of Platelet-Derived Microparticles and Nanoparticles in Medical Technology 2010-2020
Current Molecular Medicine Critical Role of Hypoxia Sensor - HIF-1α in VEGF Gene Activation. Implications for Angiogenesis and Tissue Injury Healing
Current Medicinal Chemistry Non-Invasive Biomarkers of Lung Inflammation in Smoking Subjects
Current Medicinal Chemistry Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Herb-Drug Interactions: An Insight into Cardiovascular Diseases Based on Case Reports
Cardiovascular & Hematological Agents in Medicinal Chemistry Systemic Sclerosis at the Cellular Level: Molecular Pathways of Pathogenesis and its Implication on Future Drug Design
Current Medicinal Chemistry An Overview of FDA Regulatory Requirements for Vascular Devices
Applied Drug Research, Clinical Trials and Regulatory Affairs Filling the Gaps in the Aβ Cascade Hypothesis of Alzheimers Disease
Current Alzheimer Research